Gilead Sciences (GILD) Stock Forecast & Price Target

$129.83 -5.01 (-3.72%)

Closing price 04:00 PM Eastern

Extended Trading

$130.16 +0.33 (+0.26%)

As of 07:59 PM Eastern

Compare

Gilead Sciences - Analysts' Recommendations and Stock Price Forecast (2026)

Consensus Rating

Moderate Buy

Based on 29 Analyst Ratings

Sell
0

Hold
3

Buy
26

Based on 29 Wall Street analysts who have issued ratings for Gilead Sciences in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 29 analysts, 3 have given a hold rating, and 26 have given a buy rating for GILD.

Consensus Price Target

$159.04
22.50% Upside

According to the 29 analysts' twelve-month price targets for Gilead Sciences, the average price target is $159.04. The highest price target for GILD is $180.00, while the lowest price target for GILD is $120.00. The average price target represents a forecasted upside of 22.50% from the current price of $129.83.

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Get the Latest News and Ratings for GILD and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Gilead Sciences and its competitors.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

GILD Analyst Ratings Over Time

Type	Current Forecast 7/10/25 to 7/10/26	1 Month Ago 6/10/25 to 6/10/26	3 Months Ago 4/11/25 to 4/11/26	1 Year Ago 7/10/24 to 7/10/25
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	2 Strong Buy rating(s)
Buy	26 Buy rating(s)	25 Buy rating(s)	24 Buy rating(s)	14 Buy rating(s)
Hold	3 Hold rating(s)	4 Hold rating(s)	4 Hold rating(s)	9 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$159.04	$156.93	$156.42	$111.38
Forecasted Upside	22.50% Upside	29.18% Upside	12.51% Upside	-2.76% Downside
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy	Moderate Buy

GILD Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

GILD Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Gilead Sciences Stock vs. The Competition

Type	Gilead Sciences	Medical Companies	Broader Market
Consensus Rating Score	2.90	2.30	2.52
Consensus Rating	Moderate Buy	Hold	Moderate Buy
Predicted Upside	22.44% Upside	688.51% Upside	13.79% Upside
News Sentiment Rating	Positive News See Recent GILD News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export

Date	Brokerage	Analyst	Action	Rating	Price Target	Report Date Upside/Downside
7/8/2026	Morgan Stanley 3 of 5 stars	Matthew Harrison 3 of 5 stars	Lower Target	Overweight	$168.00 ➝ $166.00	+22.39%
7/7/2026	Royal Bank Of Canada 3 of 5 stars	Brian Abrahams 4 of 5 stars	Lower Target	Sector Perform	$122.00 ➝ $120.00	-10.92%
7/7/2026	Truist Financial 3 of 5 stars	Gregory Renza Not Rated	Lower Target	Buy	$157.00 ➝ $156.00	+20.36%
7/6/2026	HSBC Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Rajesh Kumar Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Upgrade	Hold ➝ Buy	$133.00 ➝ $155.00	+18.08%
7/6/2026	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Carter Gould Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	Overweight	$155.00	+18.08%
5/28/2026	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Downgrade	Buy (B) ➝ Buy (B-)
5/20/2026	Maxim Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Michael Okunewitch Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Upgrade	Hold ➝ Buy	$165.00	+26.44%
5/19/2026	Daiwa Securities Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Lower Target	Outperform	$161.00 ➝ $150.00	+14.65%
5/11/2026	Rothschild & Co Redburn Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Lower Target		$170.00 ➝ $167.00	+25.18%
5/8/2026	Leerink Partners Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Lower Target		$148.00 ➝ $146.00	+11.17%
From the man who predicted 2008 crash… (Ad) Porter Stansberry, founder of one of the largest financial research firms in the world, says he's breaking the biggest story of his 26-year career - an economic shift not seen since 1776. From the government taking stakes in Intel, Lithium Americas, and MP Materials, to sweeping political changes reshaping the economy, Stansberry argues a rare 'New 1776 Moment' is already underway. One Nobel Prize winner calls it a dividing line for all of society. His presentation covers the stocks to buy, the stocks to sell, and three money moves to position yourself on the right side of this shift. Watch Porter Stansberry's full briefing and learn how to prepare now
4/17/2026	The Goldman Sachs Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Boost Target	Neutral	$125.00 ➝ $130.00	-5.41%
4/13/2026	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Geoff Meacham Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Buy	$156.00 ➝ $165.00	+19.83%
3/10/2026	Jefferies Financial Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Akash Tewari Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Initiated Coverage	Buy	$180.00	+22.76%
2/23/2026	Needham & Company LLC Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Joseph Stringer Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	Buy	$170.00	+13.53%
2/20/2026	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Emily Field Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Initiated Coverage	Equal Weight	$155.00	+2.57%
2/19/2026	Argus Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Boost Target	Buy	$135.00 ➝ $165.00	+9.18%
2/18/2026	Mizuho Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Boost Target	Outperform	$140.00 ➝ $170.00	+11.30%
2/12/2026	Wolfe Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Alexandria Hammond Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Outperform	$155.00 ➝ $170.00	+9.11%
2/11/2026	Sanford C. Bernstein Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Courtney Breen Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	Outperform	$160.00	+3.14%
2/11/2026	Bank of America Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Set Target	Buy	$162.00	+4.03%
2/11/2026	Oppenheimer Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Boost Target	Outperform	$128.00 ➝ $165.00	+5.91%
2/11/2026	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Boost Target	Buy	$135.00 ➝ $155.00	-0.51%
2/11/2026	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Tyler Van Buren Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Buy	$145.00 ➝ $160.00	+2.70%
2/11/2026	Wells Fargo & Company Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Mohit Bansal Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Overweight	$150.00 ➝ $165.00	+12.07%
2/11/2026	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Chris Schott Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Overweight	$150.00 ➝ $160.00	+8.67%
2/11/2026	Scotiabank Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Louis Chen Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Sector Outperform	$140.00 ➝ $177.00	+20.22%
1/26/2026	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Michael Yee Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Buy	$145.00 ➝ $155.00	+12.54%
1/26/2026	BMO Capital Markets Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Evan David Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Outperform	$135.00 ➝ $150.00	+10.35%
9/5/2025	Dbs Bank Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Upgrade	Moderate Buy
2/13/2025	DZ Bank Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Upgrade	Hold ➝ Buy	$108.00	+4.54%
2/12/2025	Piper Sandler Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Joseph Catanzaro Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Overweight	$105.00 ➝ $110.00	+6.33%
11/7/2024	Robert W. Baird Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Boost Target	Neutral	$80.00 ➝ $95.00	-2.30%
8/9/2024	Evercore Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	U. Raffat Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Upgrade	Strong-Buy

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Friday at 11:52 PM ET.

Should I Buy Gilead Sciences Stock? GILD Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Friday, July 10, 2026. Please send any questions or comments about these Gilead Sciences pros and cons to contact@marketbeat.com.

Gilead Sciences
Bull Case

Here are some ways that investors could benefit from investing in Gilead Sciences, Inc.:

The company has a strong focus on antiviral therapies, particularly for HIV and viral hepatitis, which are critical areas of high unmet medical need.
Gilead Sciences, Inc. has a solid dividend payout ratio of approximately 44.69%, indicating a commitment to returning value to shareholders.
Institutional investors hold a significant portion of the company's stock, around 83.67%, which often reflects confidence in the company's long-term prospects.
The current stock price is around $80, which may present a buying opportunity for investors looking for value in the biopharmaceutical sector.
Recent expansions into oncology and cell therapy indicate Gilead's commitment to diversifying its product portfolio and addressing broader health challenges.

Gilead Sciences
Bear Case

Investors should be bearish about investing in Gilead Sciences, Inc. for these reasons:

Despite its strong product portfolio, Gilead faces intense competition in the biopharmaceutical industry, which could impact market share and profitability.
Recent market volatility may affect stock performance, and investors should be cautious of potential fluctuations in the stock price.
There are ongoing regulatory challenges in the pharmaceutical industry that could delay product approvals and impact revenue streams.
Gilead's reliance on a few key products for a significant portion of its revenue could pose risks if those products face market challenges.
Investors may be concerned about the company's ability to innovate and develop new therapies in a rapidly evolving healthcare landscape.

GILD Forecast - Frequently Asked Questions

According to the research reports of 29 Wall Street equities research analysts, the average twelve-month stock price forecast for Gilead Sciences is $159.04, with a high forecast of $180.00 and a low forecast of $120.00.

29 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Gilead Sciences in the last twelve months. There are currently 3 hold ratings and 26 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" GILD shares.

According to analysts, Gilead Sciences's stock has a predicted upside of 22.50% based on their 12-month stock forecasts.

Over the previous 90 days, Gilead Sciences's stock had 4 upgrades and 1 downgrade by analysts.

Gilead Sciences has been rated by research analysts at Cantor Fitzgerald, Citigroup, Daiwa Securities Group, HSBC, Leerink Partners, Maxim Group, Morgan Stanley, Rothschild & Co Redburn, Royal Bank Of Canada, The Goldman Sachs Group, Truist Financial, and Weiss Ratings in the past 90 days.

Analysts like Gilead Sciences more than other "medical" companies. The consensus rating for Gilead Sciences is Moderate Buy while the average consensus rating for "medical" companies is Hold. Learn more on how GILD compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Analyst Ratings

Top-Rated Stocks

More Ratings Tools

Brokerages With Gilead Sciences Recommendations

This page (NASDAQ:GILD) was last updated on 7/10/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Gilead Sciences (GILD) Stock Forecast & Price Target

Gilead Sciences - Analysts' Recommendations and Stock Price Forecast (2026)

Consensus Rating

Consensus Price Target

GILD Analyst Ratings Over Time

GILD Analyst Recommendations By Month

GILD Price Targets by Month

Gilead Sciences Stock vs. The Competition

Recent Analyst Forecasts and Stock Ratings

Should I Buy Gilead Sciences Stock? GILD Pros and Cons Explained

Gilead Sciences
Bull Case

Gilead Sciences
Bear Case

GILD Forecast - Frequently Asked Questions

Stock Forecasts and Research Tools

Today's Analyst Ratings

Top-Rated Stocks

More Ratings Tools

Brokerages With Gilead Sciences Recommendations

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Gilead Sciences (GILD) Stock Forecast & Price Target

Gilead Sciences - Analysts' Recommendations and Stock Price Forecast (2026)

Consensus Rating

Consensus Price Target

GILD Analyst Ratings Over Time

GILD Analyst Recommendations By Month

GILD Price Targets by Month

Gilead Sciences Stock vs. The Competition

Recent Analyst Forecasts and Stock Ratings

Should I Buy Gilead Sciences Stock? GILD Pros and Cons Explained

Gilead Sciences Bull Case

Gilead Sciences Bear Case

GILD Forecast - Frequently Asked Questions

What is Gilead Sciences' forecast for 2026?

Should I buy or sell Gilead Sciences stock right now?

Does Gilead Sciences's stock price have much upside?

Has Gilead Sciences been upgraded or downgraded by Wall Street analysts recently?

What analysts cover Gilead Sciences?

Do Wall Street analysts like Gilead Sciences more than its competitors?

Stock Forecasts and Research Tools

Today's Analyst Ratings

Top-Rated Stocks

More Ratings Tools

Brokerages With Gilead Sciences Recommendations

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

Gilead Sciences
Bull Case

Gilead Sciences
Bear Case